LAG3 and autoimmune disease: Importantly, this treatment did not result in any immune-related adverse effects in other organs.[61] Furthermore, LAG-3 has been identified as a prognostic biomarker for certain autoimmune diseases.[62–64] In the case of patients with rheumatoid arthritis, the presence of peripheral sLAG-3 is primarily derived from the cleaved surface LAG-3 of Tregs.